Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Silexion Therapeutics ( (SLXN) ) has shared an announcement.
On April 28, 2026, Silexion Therapeutics announced it had successfully submitted a Clinical Trial Application to Germany’s BfArM via the EU Clinical Trials Information System for a planned Phase 2/3 trial of its lead siRNA candidate, SIL204, in patients with KRAS-driven locally advanced pancreatic cancer, with Germany acting as the Reporting Member State for the broader EU program. This regulatory step, informed by prior positive Scientific Advice from BfArM and following recent approval of the same trial in Israel, positions Silexion to initiate a multinational Phase 2/3 study in the second quarter of 2026, testing SIL204 alongside standard chemotherapy using a dual-route administration strategy, and underscores the company’s push to establish a significant foothold in addressing the large unmet need in KRAS-mutated pancreatic cancer across major jurisdictions.
The most recent analyst rating on (SLXN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral.
The score is held down primarily by weak financial durability (no revenue and ongoing cash burn) and a technically weak trend (price below major moving averages with negative MACD). Offsetting factors include oversold readings that may support a near-term rebound and a positive clinical/regulatory milestone, but valuation support is limited with a negative P/E and no dividend.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp. is a clinical-stage, oncology-focused biotechnology company developing RNA interference (RNAi) therapies for solid tumors driven by mutated KRAS, one of the most common oncogenic drivers in human cancers. The company previously ran a Phase 2a trial of a first-generation candidate showing a positive trend versus chemotherapy alone and is now advancing its second-generation siRNA therapy, SIL204, toward clinical trials in Israel and the European Union for locally advanced pancreatic cancer.
Average Trading Volume: 50,220
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.19M
Learn more about SLXN stock on TipRanks’ Stock Analysis page.